Instem Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Phil Reason

Chief Executive Officer (CEO)

UK£300.0k

Compensación total

Porcentaje del salario del CEO	78.7%
Permanencia del CEO	no data
Participación del CEO	3.2%
Permanencia media de la dirección	4.8yrs
Promedio de permanencia en la Junta Directiva	1.9yrs

Actualizaciones recientes de la dirección

Recent updates

Is Instem plc's (LON:INS) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Mar 03

Shareholders Are Thrilled That The Instem (LON:INS) Share Price Increased 190%

Jan 29

Calculating The Intrinsic Value Of Instem plc (LON:INS)

Dec 25

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Phil Reason en comparación con los beneficios de Instem?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2023	n/a	n/a	UK£3m
Mar 31 2023	n/a	n/a	UK£4m
Dec 31 2022	UK£300k	UK£236k	UK£5m
Sep 30 2022	n/a	n/a	UK£3m
Jun 30 2022	n/a	n/a	UK£2m
Mar 31 2022	n/a	n/a	UK£2m
Dec 31 2021	UK£279k	UK£204k	UK£2m
Sep 30 2021	n/a	n/a	UK£2m
Jun 30 2021	n/a	n/a	UK£2m
Mar 31 2021	n/a	n/a	UK£2m
Dec 31 2020	UK£276k	UK£226k	UK£2m
Sep 30 2020	n/a	n/a	UK£1m
Jun 30 2020	n/a	n/a	UK£339k
Mar 31 2020	n/a	n/a	-UK£292k
Dec 31 2019	UK£261k	UK£223k	-UK£923k
Sep 30 2019	n/a	n/a	UK£418k
Jun 30 2019	n/a	n/a	UK£2m
Mar 31 2019	n/a	n/a	UK£2m
Dec 31 2018	UK£243k	UK£207k	UK£1m
Sep 30 2018	n/a	n/a	UK£1m
Jun 30 2018	n/a	n/a	UK£1m
Mar 31 2018	n/a	n/a	UK£1m
Dec 31 2017	UK£246k	UK£210k	UK£642k
Sep 30 2017	n/a	n/a	UK£470k
Jun 30 2017	n/a	n/a	UK£297k
Mar 31 2017	n/a	n/a	UK£678k
Dec 31 2016	UK£241k	UK£194k	UK£1m

Compensación vs. Mercado: La compensación total de Phil($USD375.21K) está por debajo de la media de empresas de tamaño similar en el mercado UK ($USD739.97K).

Compensación vs. Ingresos: La compensación de Phil ha sido consistente con los resultados de la empresa en el último año.

CEO

Phil Reason (61 yo)

no data

Permanencia

UK£300,000

Compensación

Mr. Phil J. Reason serves as the Chief Executive Officer of Instem LSS Limited, Instem Associates Limited and Instem plc (Instem Life Science Systems plc). Mr. Reason is an experienced chief executive who...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Phil Reason	CEO & Executive Director	no data	UK£300.00k	3.2% £ 6.4m
Nigel Goldsmith	CFO, Secretary & Executive Director	12yrs	UK£166.00k	0.042% £ 83.0k
Marybeth Thompson	Chief Operating Officer	6.8yrs	sin datos	sin datos
Gordon Baxter	Chief Scientific Officer	no data	sin datos	sin datos
Mark Poggi	Executive Vice President of Global Sales	less than a year	sin datos	sin datos
Eve Leconte	Chief People & Culture Officer	4.8yrs	sin datos	sin datos
Mike Harwood	Chief Product Officer	no data	sin datos	sin datos
Gregor Grant	Executive Vice President of Preclinical Solutions	no data	sin datos	sin datos
John Leveille	Executive Vice President of Clinical Trial Acceleration	less than a year	sin datos	1.79% £ 3.6m

4.8yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de INS se considera experimentado (4.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Phil Reason	CEO & Executive Director	no data	UK£300.00k	3.2% £ 6.4m
Nigel Goldsmith	CFO, Secretary & Executive Director	12yrs	UK£166.00k	0.042% £ 83.0k
Riaz Bandali	Independent Non-Executive Director	1.9yrs	UK£36.00k	sin datos
Michael McGoun	Non-Executive Director	no data	UK£40.00k	sin datos
David Gare	Non-Executive Chairman	no data	UK£65.00k	5.52% £ 11.0m
Mary Dolson	Independent Non-Executive Director	less than a year	sin datos	sin datos

1.9yrs

Permanencia media

62.5yo

Promedio de edad

Junta con experiencia: La junta directiva de INS no se considera experimentada (1.9 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Instem Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Less than half of directors are independent

Instem plc, Annual General Meeting, Jun 27, 2023

Instem plc Announces Board and Committee Appointments

CEO & Executive Director exercised options and sold UK£143k worth of stock

Less than half of directors are independent

Instem plc, Annual General Meeting, Jun 09, 2022

Recent updates

Instem Enables Clients to Leverage ICH S1B Weight of Evidence Guideline

ArchiMed SAS agreed completed the acquisition of Instem plc (AIM : INS) from group of sellers.

ArchiMed SAS agreed completed the acquisition of Instem plc (AIM : INS) from group of sellers.

Instem's Shares to Trading on AIM Expected to Be Cancelled on 21 November 2023

Here's Why We Think Instem (LON:INS) Might Deserve Your Attention Today

New minor risk - Earnings quality

ArchiMed SAS agreed to acquire Instem plc (AIM : INS) from group of sellers for approximately £190 million.

ArchiMed SAS agreed to acquire Instem plc (AIM : INS) from group of sellers for approximately £190 million.

An Intrinsic Calculation For Instem plc (LON:INS) Suggests It's 29% Undervalued

Less than half of directors are independent

Instem plc, Annual General Meeting, Jun 27, 2023

Ennov SA acquired Samarind Ltd from Instem plc (AIM:INS).

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Instem plc Announces Board and Committee Appointments

CEO & Executive Director exercised options and sold UK£143k worth of stock

Price target increased to UK£10.10

Less than half of directors are independent

Instem Unveils New Additions to Its Leading Computational Toxicology Software Suite

First half 2022 earnings released: EPS: UK£0.057 (vs UK£0.048 in 1H 2021)

Instem plc Announces Settlement of Historical Licence Dispute

Instem plc to Report First Half, 2022 Results on Sep 27, 2022

Instem plc, Annual General Meeting, Jun 09, 2022

European Medicines Agency Awards Research Grant to Instem

Instem plc Receives European Medicines Agency Research Grant

Full year 2021 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Instem plc to Report Fiscal Year 2021 Results on Apr 26, 2022

Investor sentiment deteriorated over the past week

CEO & Executive Director exercised options and sold UK£298k worth of stock

Instem plc Provides Revenue Guidance for the Year Ended 31 December 2021

Instem plc (LON:INS) Shares Could Be 45% Below Their Intrinsic Value Estimate

Instem plc Announces the Release of the Latest Edition of Its Leadscope Model Applier Computational Toxicology Software Solution

First half 2021 earnings released: EPS UK£0.048 (vs UK£0.095 in 1H 2020)

Instem plc's (LON:INS) Intrinsic Value Is Potentially 44% Above Its Share Price

Instem plc (AIM:INS) acquired PDS Pathology Data Systems Ltd. for CHF 14.2 million.

Instem plc (AIM:INS) acquired PDS Pathology Data Systems Ltd for CHF 14.2 million.

Full year 2020 earnings released: EPS UK£0.12 (vs UK£0.057 loss in FY 2019)

Instem plc (AIM:INS) acquired The Edge Software Consultancy Ltd. for £8.5 million.

Is Instem plc's (LON:INS) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

New 90-day high: UK£5.20

Shareholders Are Thrilled That The Instem (LON:INS) Share Price Increased 190%

New 90-day high: UK£5.08

Calculating The Intrinsic Value Of Instem plc (LON:INS)

Instem plc Provides New Business Update

Instem Launches in Silico Toxicology Service

New 90-day low: UK£4.40

First half earnings released

New 90-day high - UK£5.45

Instem plc has completed a Follow-on Equity Offering in the amount of £15.750002 million.

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media

Promedio de edad